Skip to main content
SpringerLink
Log in

Effect of postoperative intrapleural instillations of interleukin-2 in patients with malignant pleurisy due to lung cancer

  • Research Articles
  • Published:
Biotherapy

Abstract

Thirteen patients with resectable lung cancer and concomitant malignant pleurisy which could not be detected by preoperative chest roentogenograms were treated with surgical resection of the primary lesions and postoperative intrapleural instillations of interleukin-2 (IL-2). All of the patients demonstrated disappearance of cancer cells from pleural effusion after the IL-2 therapy. Four of the 13 patients survived over 5 years and 2 of them are in disease free state at this moment (January 31, 1993). The first recurrent sites were distant organs in 8 of 11 patients with recurrence and lymph nodes in 3 of them. No pleural recurrence was observed. These results indicate that the postoperative intrapleural IL-2 therapy may be one of hopeful adjuvant therapies in patients with resectable lung cancer and concomitant malignant pleurisy, although distant metastasis and lymph node recurrence could not be suppressed completely.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

IL-2:

interleukin-2

TIL:

tumor infiltrating lymphocyte

LAK:

lymphokine activated killer

TNF:

tumor necrosis factor

References

  1. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Change AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson CG, Reichert CM. Observation on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313:1485–92.

    PubMed  Google Scholar 

  2. Kradin RL, Boyle LA, Preffer FI, Callahan RJ, Barlai-Kovach M, Strauss HW, Dubinett S, Kurnick JT. Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer. Cancer Immunol Immunother 1987; 24:76–85.

    PubMed  Google Scholar 

  3. Belldegrun A, Kasid A, Uppenkamp M, Topalian SL, Rosenberg SA. Human tumor infiltrating lymphocytes; Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. J Immunol 1989; 142:4520–6.

    PubMed  Google Scholar 

  4. Yasumoto K, Takeo S, Yano T, Nakahashi H, Nagashima A, Sugimachi K, Nomoto K. Role of tumor infiltrating lymphocytes in host defence mechanisms against lung cancer. J Surg Oncol 1988; 38:221–6.

    PubMed  Google Scholar 

  5. Miescher S, Whiteside TL, Carrel S, von Fliedner W. Functional properties of tumor-inflicting and blood lymphocytes in patients with solid tumors; Effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 1986; 136:1899–907.

    PubMed  Google Scholar 

  6. Mull LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 1987; 138:989–95.

    PubMed  Google Scholar 

  7. Belldegrun A, Muul LM, Rosenberg SA. Interleukin-2-expanded tumor-infiltrating lymphocytes in human renal cell cancer; isolation, characterization, and antitumor activity. Cancer Res 1988; 48:206–14.

    PubMed  Google Scholar 

  8. Heo DS, Whiteside TL, Johnson JT, Chen K, Barnes EL, Herberman RB. Long-term interleukin-2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck Cancer Res 1987; 47:6353–62.

    PubMed  Google Scholar 

  9. Yasumoto K, Miyazaki K, Nagashima A, Ishida T, Kuda T, Yano T, Sugimachi K, Nomoto K. Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. Cancer Res 1987; 47:2184–87.

    PubMed  Google Scholar 

  10. Yasumoto K, Ogura T. Intrapleural application of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. A multi-institutional cooperative study. Biother 1991; 3:345–9.

    Google Scholar 

  11. Mattews MJ, Kanhouwa S, Pickren J, Robinette D. Frequency of residual and metastatic tumor in patients undergoing curative surgical resection in lung cancer. Cancer Chemother Rep 1973; 4:63–7.

    Google Scholar 

  12. Paulson DL. The survival rate in superior sulcus tumors treated by presurgical irradiation. JAMA 1966; 4:342.

    Google Scholar 

  13. McKneally MF, Maver C, Lininger L, Kausel HW, McIlduff JB, Older TM, Foster ED, Alley RD. Four-year follow-up on the Albany experience with intrapleural BCG in lung cancer. J Thorac Cardiovasc Surg 1981; 81:485–92.

    PubMed  Google Scholar 

  14. Yasumoto K, Yaita H, Ohta M, Azuma I, Nomoto K, Inokuchi K, Yamamura Y. Randomly controlled study of chemotherapy versus chemoimmunotherapy in post-operative lung cancer patients. Cancer Res 1985; 45:1413–7.

    PubMed  Google Scholar 

  15. Fujisawa T, Yamaguchi Y, Kimura H, Arita M, Baba M, Shiba M. Adjuvant immunotherapy of primary resected lung cancer with transfer factor. Cancer 1984; 54:663–9.

    PubMed  Google Scholar 

  16. Edwards FR, Whitewell F. Use of BCG as an immuno-stimulant in the surgical treatment of immunostimulant in the surgical treatment of carcinoma of lung-a five year follow-up report. Thorax 1978; 33:250–2.

    PubMed  Google Scholar 

  17. Mountain CF, Gail MH. Surgical adjuvant intrapleural BCG treatment for stage I non-small cell lung cancer. Preliminary report of the National Cancer Institute Lung Cancer Study Group. J Thorac Cardiovasc Surg 1981; 82:649–57.

    PubMed  Google Scholar 

  18. Ludwig Lung Cancer Study Group. Adverse effect of intrapleuralCorynebacterium parvum as adjuvant therapy in resected stage I and II non-small cell carcinoma of the lung. J Thorac Cardiovasc Surg 1985; 89:842–7.

    Google Scholar 

  19. Morgan DA, Ruscetti FW, Gallow R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science (Wash DC) 1976; 193:1007–8.

    Google Scholar 

  20. Baker PE, Gillis S, Ferm MM, Smith KA. The effect of T cell growth factor on the generation of cytolytic T cells. J Immunol 1982; 121:2168–73.

    Google Scholar 

  21. Henney CS, Kuribayashi K, Kern DE, Gillis S. Interleukin-2 augments natural killer cell activity. Nature (Lond) 1981; 291:335–8.

    Google Scholar 

  22. Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 1981; 41:4420–5.

    PubMed  Google Scholar 

  23. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155:1823–41.

    PubMed  Google Scholar 

  24. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210:474–85.

    PubMed  Google Scholar 

  25. Bindon C, Czerniecki M, Ruell P, Edwards A, McCarthy WH, Harris R, Hersey P. Clearance rates and systemic effects of intravenously administered interleukin-2 (IL-2) containing preparations in human subjects. Br J Cancer 1983; 47:123–33.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chest Surgery, Kitakyushu Medical Center, Bashyaku 2-1-1, Kokura-kita-ku, 802, Kitakyushu, Japan

    Kosei Yasumoto & Akira Nagashima

  2. Respiratory Disease Center, Matsuyama Red Cross Hospital, Bunkyo-cho 1, 790, Matsuyama, Japan

    Hisashi Nakahashi

  3. Second Department of Surgery, Kyushu University Medical School, Maidashi 3-1-1, Higashi-ku, 812, Fukuoka, Japan

    Teruyoshi Ishida & Keizo Sugimachi

  4. Department of Immunology, Medical Institute of Bioregulation, Kyushu University, Maidashi 3-1-1, Higashi-ku, 812, Fukuoka, Japan

    Kikuo Nomoto

Authors
  1. Kosei Yasumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akira Nagashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hisashi Nakahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Teruyoshi Ishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keizo Sugimachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kikuo Nomoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yasumoto, K., Nagashima, A., Nakahashi, H. et al. Effect of postoperative intrapleural instillations of interleukin-2 in patients with malignant pleurisy due to lung cancer. Biotherapy 6, 133–138 (1993). https://doi.org/10.1007/BF01877426

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01877426

Key words

Search

Navigation